NCT00472576View on ClinicalTrials.gov

Antidepressant Effects of NR2B in Major Depression

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Major Depression
Interventions
DRUG

MK-0657

Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)

DRUG

Placebo

Daily double-blind administration of placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT00472576 - Antidepressant Effects of NR2B in Major Depression | Biotech Hunter | Biotech Hunter